Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$23.41 -3.7%	$19.94	$13.36 ▼ $32.27	$753.52M	1.43	323,621 shs	264,707 shs
GHRS GH Research	$13.18 +0.8%	$13.87	$6.00 ▼ $20.50	$685.76M	0.98	332,786 shs	209,889 shs
MRVI Maravai LifeSciences	$2.40 -2.0%	$2.45	$1.66 ▼ $9.60	$612.86M	0.28	2.39 million shs	863,663 shs
SLS SELLAS Life Sciences Group	$1.91	$1.79	$0.77 ▼ $2.27	$201.12M	2.26	2.55 million shs	1.90 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+17.16%	+13.02%	+31.92%	-14.13%
GHRS GH Research	0.00%	+2.27%	-9.79%	+17.10%	+13.94%
MRVI Maravai LifeSciences	0.00%	-6.13%	-8.92%	+10.36%	-72.50%
SLS SELLAS Life Sciences Group	0.00%	+17.18%	+6.11%	+1.06%	+44.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNTH Dianthus Therapeutics	1.161 of 5 stars	3.5	0.0	0.0	1.7	0.8	0.0
GHRS GH Research	1.4104 of 5 stars	3.4	3.0	0.0	0.0	0.8	0.0
MRVI Maravai LifeSciences	4.0087 of 5 stars	3.1	3.0	4.4	2.9	0.8	0.6
SLS SELLAS Life Sciences Group	2.8892 of 5 stars	3.5	2.0	0.0	3.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	130.67% Upside
GHRS GH Research	2.88	Moderate Buy	$32.00	142.79% Upside
MRVI Maravai LifeSciences	2.25	Hold	$5.75	139.58% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	266.49% Upside

Current Analyst Ratings Breakdown

Latest SLS, DNTH, GHRS, and MRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	MRVI Maravai LifeSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$7.00 ➝ $5.00
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$4.85M	155.24	N/A	N/A	$11.91 per share	1.97
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
MRVI Maravai LifeSciences	$259.18M	2.36	$0.61 per share	3.96	$2.28 per share	1.05
SLS SELLAS Life Sciences Group	$1M	201.12	N/A	N/A	$0.13 per share	14.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.36	N/A	N/A	N/A	-90.03%	-17.60%	-9.30%	11/6/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	N/A	N/A	N/A	N/A	-132.51%	-92.79%	11/12/2025 (Estimated)

Latest SLS, DNTH, GHRS, and MRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	13.12	13.12
GHRS GH Research	N/A	29.49	29.49
MRVI Maravai LifeSciences	0.68	5.16	4.49
SLS SELLAS Life Sciences Group	N/A	4.91	4.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
GHRS GH Research	56.90%
MRVI Maravai LifeSciences	50.25%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	8.15%
GHRS GH Research	N/A
MRVI Maravai LifeSciences	2.11%
SLS SELLAS Life Sciences Group	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	32.19 million	26.86 million	Optionable
GHRS GH Research	10	52.03 million	N/A	Optionable
MRVI Maravai LifeSciences	610	255.36 million	249.97 million	Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	104.03 million	Not Optionable

SLS, DNTH, GHRS, and MRVI Headlines

Recent News About These Companies

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

August 20, 2025 | marketbeat.com

SELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS)

August 20, 2025 | americanbankingnews.com

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

August 19, 2025 | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings Results

August 14, 2025 | marketbeat.com

Sellas Life Sciences Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

August 12, 2025 | msn.com

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...

August 9, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

August 7, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31, 2025 | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, DNTH, GHRS, and MRVI Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$23.41 -0.89 (-3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$23.42 +0.02 (+0.06%)

As of 04:10 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

GH Research NASDAQ:GHRS

$13.18 +0.10 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$13.36 +0.19 (+1.40%)

As of 05:11 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Maravai LifeSciences NASDAQ:MRVI

$2.40 -0.05 (-2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 0.00 (0.00%)

As of 04:10 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.91 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.01 (+0.26%)

As of 05:32 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time